hotspot -WSS

hotspot

author：explore 2025-09-02 22:23:38 - browse：3213

portrait of Jennifer Adair -- coverage from STAT — Jennifer Adair develops scalable, low cost gene therapies at the Fred Hutchinson Cancer Center and helped found the Global Gene Therapy Initiative. Fred Hutch News Service

BALTIMORE — Gene and cell therapies have transformed a handful of devastating disorders in the U.S. and Europe, with more treatments on the way. But those technologies have largely failed to reach most of the world.

These lags are ubiquitous in the current drug development system, where new therapies are approved in wealthy countries and then slowly leak out to low- and middle-income countries, many years later. In the case of gene therapy, that means countries most affected by a disease such as sickle cell may wait decades to access a curative therapy.

For the last few years, a handful of researchers in the U.S. and around the world have tried to find ways of ensuring global access to these technologies. In 2020, they formed the Global Gene Therapy Initiative, with an initial goal of setting up a gene therapy clinical trial for a hemoglobinopathy — such as a disease like sickle cell or beta thalassemia — or HIV in two different low- and middle-income countries by 2024.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Seattle police shoot person suspected in downtown stabbing

knowledge

WSS

New warning issued for rebooking air travel after delays, cancellations

Gain of function research would be limited under House proposal

No Labels group has 'steep climb,' but third party 'worth trying': Larry Hogan

India sets sights on home

Why the Crimean Bridge is key to Russia's war in Ukraine

Congress must reauthorize a committee to support older Americans

leisure time

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

The kidney, in all its complexity, is captured in a new atlas

Hollywood unions extend contract negotiations for actors

Plane’s emergency slide plummets from sky, hits Chicago home

Anesthesiologist group: stop taking Ozempic before surgery

DOJ, FTC to increase scrutiny of all types of health care mergers

Psychedelics group wrestles with new pharma identity

A daunting task: navigating dual Medicare, Medicaid eligibility

Trump demands the U.S. pay no more for drugs than other countries … again

Resistance to cancer drugs: A new genetic explanation

explore

Poor hospice wound care hurts patients and families

Does good food count as health care? Study aims to find out

FDA's Woodcock to retire early next year

A daunting task: navigating dual Medicare, Medicaid eligibility

Poor hospice wound care hurts patients and families

Couple fighting to bring baby home from Mexico are finally reunited

focus

hotspot

knowledge

entertainment